

# **Safety of remibrutinib in patients with chronic spontaneous urticaria: Results from the Phase 3 REMIX-1 and REMIX-2 studies**

*P. Staubach, S. Saini, A.M. Giménez-Arnau, M. Hide, M. Lebwohl, G. Sussman, S. Haemmerle, K. Lheritier, E-D. Martzloff, A. Zharkov, M. Maurer*

***Please click [HERE](#) to subscribe to news alerts of the Novartis Urticaria Knowledge Center and to receive an email notification once the publication is available***

***Or use this [LINK](#) to access the abstract after 3<sup>rd</sup> June 2024, once it is available at the congress website***